- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Resource Allocation in the Treatment of Dry Eye Disease
A panel of medical experts discuss the shift from intervention to prevention in the management of dry eye disease, as well as perspectives on resource allocation.
EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments
EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease
EP: 3.Navigating Different Subtypes of Dry Eye Disease
EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes
EP: 5.Updating Formularies: Considerations for Dry Eye Disease
EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease
EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease
EP: 8.Resource Allocation in the Treatment of Dry Eye Disease
EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease
EP: 10.Annual Health Care Costs of Managing Dry Eye Disease
EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease
EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease
EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease
EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Haumschild asks about aligning dry eye disease (DED) management with overall health care spending trends. Parekh notes the shift from intervention to prevention. Earlier DED detection enables disease-modifying therapy like artificial tears and behavioral changes for sustained benefits vs allowing progression and irreversible damage. This prevents exponentially higher costs with severe late-stage DED. Upfront DED investment reflects a value shift toward comprehensive eye care beyond surgery and glasses. The average DED patient age has dropped into the 30s, driven by digital device use, representing expanded need. Central corneal staining in young patients highlights the growth of DED. Broad DED coverage and early access are thus increasingly warranted from clinical, social, and economic standpoints.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status
February 18th 2025In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected overall survival but not progression-free survival.
Read More
